中银国际：升泰格医药(03347)目标价至51港元 维持“买入”评级

Core Viewpoint - The report from Zhongyin International indicates that Tiger Medical (03347) is facing ongoing challenges in the domestic biotechnology industry, with weak demand and financing restrictions impacting project quantity and pricing [1] Company Performance - The half-year performance of Tiger Medical reflects a contraction in profitability due to the aforementioned challenges [1] - However, the expansion of overseas business is helping to mitigate some of the impacts [1] Future Outlook - Looking ahead, a recovery in domestic financing and new overseas orders may support gradual improvement in performance, although the timing remains uncertain [1] - The stock rating is maintained at "Buy," with the target price increased from HKD 40 to HKD 51 [1]